INNOVIVA, INC. (INVA) Current Ratio
- Current ratio · latest quarter: Value 16.01×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.01× | Current assets / current liabilities. $753.37M ÷ $47.06M ≈ 16.01× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 753.37M USD | Assets, Current |
| Current obligations | 47.06M USD | Liabilities, Current |
| Cash and equivalents | 570.39M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 38.97M USD | Inventory, Net |
| Payables | 4.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $753.37M | $47.06M | $570.39M | (m) | (m) | $38.97M | $4.02M | (m) | 16.01× |
| 2026-03-31 | $772.62M | $36.56M | $603.09M | (m) | (m) | $38.84M | $6.52M | (m) | 21.13× |
| 2025-12-31 | $727.51M | $49.70M | $550.94M | (m) | (m) | $39.17M | $4.97M | (m) | 14.64× |
| 2025-09-30 | $684.57M | $48.47M | $476.51M | (m) | (m) | $38.36M | $6.24M | (m) | 14.12× |
| 2025-06-30 | $651.78M | $246.56M | $397.53M | (m) | (m) | $49.00M | $5.38M | (m) | 2.64× |
| 2025-03-31 | $582.02M | $234.75M | $319.09M | (m) | (m) | $41.48M | $4.70M | (m) | 2.48× |
| 2024-12-31 | $554.31M | $236.08M | $304.96M | (m) | (m) | $33.73M | $2.13M | (m) | 2.35× |
| 2024-09-30 | $400.62M | $223.75M | $260.63M | (m) | (m) | $34.24M | $4.17M | (m) | 1.79× |
| 2024-06-30 | $358.28M | $28.21M | $217.00M | (m) | (m) | $36.66M | $2.04M | (m) | 12.70× |
| 2024-03-31 | $311.34M | $29.88M | $178.36M | (m) | (m) | $37.44M | $890.00K | (m) | 10.42× |
| 2023-12-31 | $344.22M | $38.13M | $193.51M | (m) | (m) | $40.74M | $6.72M | (m) | 9.03× |
| 2023-09-30 | $305.00M | $36.18M | $180.00M | (m) | (m) | $40.52M | $3.78M | (m) | 8.43× |
| 2023-06-30 | $323.54M | $39.40M | $173.03M | (m) | (m) | $46.85M | $4.59M | (m) | 8.21× |
| 2023-03-31 | $296.45M | $38.14M | $144.05M | (m) | (m) | $49.65M | $5.93M | (m) | 7.77× |
| 2022-12-31 | $443.51M | $134.97M | $291.05M | (m) | (m) | $55.90M | $2.94M | (m) | 3.29× |
| 2022-09-30 | $454.59M | $163.88M | $300.79M | $282.00K | (m) | $70.81M | $3.81M | (m) | 2.77× |
| 2022-06-30 | $400.33M | $125.91M | $283.58M | (m) | (m) | (m) | $4.32M | (m) | 3.18× |
| 2022-03-31 | $317.82M | $109.23M | $216.80M | (m) | (m) | (m) | $1.81M | (m) | 2.91× |
| 2021-12-31 | $313.67M | $5.81M | $201.53M | (m) | (m) | $0.00 | $27.00K | (m) | 54.02× |
| 2021-09-30 | $236.93M | $3.13M | $135.12M | (m) | (m) | (m) | $89.00K | (m) | 75.82× |
| 2021-06-30 | $148.26M | $5.37M | $43.27M | (m) | (m) | (m) | $30.00K | (m) | 27.60× |
| 2021-03-31 | $372.93M | $3.80M | $282.89M | (m) | (m) | (m) | $14.00K | (m) | 98.04× |
| 2020-12-31 | $342.06M | $6.11M | $246.49M | (m) | (m) | (m) | $66.00K | (m) | 55.98× |
| 2020-09-30 | $572.04M | $3.90M | $479.19M | $0.00 | (m) | (m) | $623.00K | (m) | 146.75× |
| 2020-06-30 | $500.19M | $5.41M | $413.15M | $4.00M | (m) | (m) | $195.00K | (m) | 92.39× |
| 2020-03-31 | $466.91M | $2.80M | $351.98M | $31.97M | (m) | (m) | $122.00K | (m) | 166.87× |
| 2019-12-31 | $431.23M | $5.37M | $278.10M | $72.75M | (m) | (m) | $10.00K | (m) | 80.29× |
| 2019-09-30 | $366.80M | $3.33M | $172.95M | $124.25M | (m) | (m) | $35.00K | (m) | 110.18× |
| 2019-06-30 | $317.69M | $7.47M | $141.95M | $107.71M | (m) | (m) | $1.14M | (m) | 42.50× |
| 2019-03-31 | $251.52M | $3.81M | $65.15M | $127.03M | (m) | (m) | $144.00K | (m) | 66.02× |
| 2018-12-31 | $199.04M | $5.70M | $62.42M | $52.49M | (m) | (m) | $11.00K | (m) | 34.92× |
| 2018-09-30 | $121.13M | $4.30M | $48.62M | $6.87M | (m) | (m) | $109.00K | (m) | 28.18× |
| 2018-06-30 | $178.66M | $6.78M | $87.23M | $20.32M | (m) | (m) | $58.00K | (m) | 26.36× |
| 2018-03-31 | $113.25M | $4.07M | $27.14M | $29.32M | (m) | (m) | $66.00K | (m) | 27.85× |
| 2017-12-31 | $200.37M | $34.74M | $73.34M | $55.74M | (m) | (m) | $601.00K | (m) | 5.77× |
| 2017-09-30 | $220.51M | $32.88M | $138.42M | $29.77M | (m) | (m) | $629.00K | (m) | 6.71× |
| 2017-06-30 | $198.06M | $27.11M | $127.63M | $7.99M | (m) | (m) | $277.00K | $15.18M | 7.31× |
| 2017-03-31 | $214.42M | $20.47M | $159.81M | $10.00M | (m) | (m) | $2.30M | (m) | 10.47× |
| 2016-12-31 | $198.05M | $20.05M | $118.02M | $32.42M | (m) | (m) | $128.00K | (m) | 9.88× |
| 2016-09-30 | $186.12M | $14.92M | $93.19M | $55.77M | (m) | (m) | $528.00K | (m) | 12.47× |
| 2016-06-30 | $190.42M | $14.63M | $112.94M | $40.92M | (m) | (m) | $137.00K | $3.27M | 13.02× |
| 2016-03-31 | $196.71M | $10.62M | $151.78M | $16.41M | (m) | (m) | $576.00K | (m) | 18.52× |
| 2015-12-31 | $214.32M | $13.49M | $159.18M | $28.10M | (m) | (m) | $818.00K | $0.00 | 15.89× |
| 2015-09-30 | $223.75M | $11.28M | $78.75M | $127.45M | (m) | (m) | $154.00K | (m) | 19.84× |
| 2015-06-30 | $243.96M | $12.21M | $149.58M | $79.68M | (m) | (m) | $462.00K | (m) | 19.97× |
| 2015-03-31 | $262.39M | $10.98M | $141.19M | $109.95M | (m) | (m) | $1.02M | (m) | 23.90× |
| 2014-12-31 | $252.18M | $13.76M | $96.80M | $143.70M | (m) | (m) | $0.00 | (m) | 18.33× |
| 2014-09-30 | $273.47M | $36.10M | $119.58M | $143.54M | $0.00 | $0.00 | $573.00K | (m) | 7.58× |
| 2014-06-30 | $353.16M | $49.99M | $208.05M | $126.42M | $0.00 | $0.00 | $1.80M | (m) | 7.06× |
| 2014-03-31 | $389.20M | $44.14M | $125.28M | $245.65M | $3.00K | $11.01M | $5.55M | (m) | 8.82× |
| 2013-12-31 | $483.20M | $84.40M | $143.51M | $321.62M | $199.00K | $10.41M | $7.58M | (m) | 5.72× |
| 2013-09-30 | $522.34M | $38.66M | $171.89M | $334.26M | (m) | $9.04M | $5.73M | (m) | 13.51× |
| 2013-06-30 | $457.23M | $38.65M | $199.24M | $243.77M | (m) | $8.24M | $4.83M | (m) | 11.83× |
| 2013-03-31 | $474.51M | $29.46M | $266.07M | $192.99M | (m) | $8.05M | $3.52M | (m) | 16.10× |
| 2012-12-31 | $261.13M | $29.97M | $94.85M | $153.64M | $0.00 | $7.51M | $5.38M | (m) | 8.71× |
| 2012-09-30 | $282.54M | $27.09M | $112.23M | $161.21M | (m) | (m) | $4.76M | (m) | 10.43× |
| 2012-06-30 | $303.38M | $25.78M | $161.10M | $134.39M | (m) | (m) | $4.99M | (m) | 11.77× |
| 2012-03-31 | $204.33M | $25.57M | $14.31M | $185.85M | (m) | (m) | $5.31M | (m) | 7.99× |
| 2011-12-31 | $244.76M | $45.50M | $44.78M | $196.14M | (m) | (m) | $5.81M | (m) | 5.38× |
| 2011-09-30 | $269.17M | $39.81M | $62.74M | $202.43M | (m) | (m) | $3.70M | (m) | 6.76× |
| 2011-06-30 | $288.63M | $35.19M | $90.66M | $193.23M | (m) | (m) | $2.17M | (m) | 8.20× |
| 2010-12-31 | $316.35M | $40.05M | $163.33M | $146.30M | (m) | (m) | $2.13M | (m) | 7.90× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |